Kidpik Corp. (PIK)

Designation supported by robust clinical  data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-“), PIK3CA WT, advanced breast cancer (“ABC”), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. As previously announced, the gedatolisib triplet demonstrated a statistically significant and clinically meaningful improvement in median progression-free survival (“PFS”) versus fulvestrant, reducing the risk of disease progression or death by 76%. The gedatolisib doublet reduced the risk of progression or death by 67% versus fulvestrant.

MALMÖ, Sweden, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”) announced today that it has issued SEK denominated senior secured floating rate bonds in a total amount of SEK 1,700 million (the “Nordic Bonds”), entered into a new sustainability-linked SEK 750 million super senior revolving credit facility agreement and intends to complete its repurchase of certain U.S. Notes (as defined below).

I maintain a hold rating on HTGC due to its premium valuation and rising concerns over portfolio quality and PIK interest income. HTGC's dividend yield remains attractive and well-covered, but increasing PIK income signals potential stress among borrowers if rates stay elevated. The portfolio is concentrated in volatile sectors and faces heightened risk from competition and macro uncertainty, despite strong first lien loan positioning.

Prospect Capital slashed its dividend by 25% in November 2024, improving dividend pay-out metrics and offering a safer dividend for passive income investors. The BDC's stock trades at a 43% discount to net asset value, reflecting investor skepticism despite improving portfolio quality and dividend coverage. Prospect Capital's non-accrual ratio improved to 0.4% QoQ, and the dividend pay-out ratio dropped to 75%, providing a margin of safety.

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Kidpik Corp. ("Kidpik" or the "Company"), an online clothing subscription-based e-commerce company, today announced that the Company received a notification letter from The Nasdaq Stock Market Hearings Panel (the "Panel") on December 20, 2024, indicating that trading in the Company's common stock on Nasdaq's Capital Market will be suspended effective at the open of business on December 26, 2024, based upon the Company's non-compliance with Listing Rule 5550(b)(1), the Exchange's minimum shareholders' equity rule (the "Equity Rule"). The Company previously announced that on October 2, 2024, the Company received a delist determination letter from the Staff of Nasdaq, notifying the Company that the Staff had determined that the Company did not provide a definitive plan evidencing its ability to achieve compliance with the continued listing requirements and to deny the Company's request for continued listing on The Nasdaq Capital Market.

ESTERO, Fla. , Dec. 13, 2024 /PRNewswire/ -- Hertz Global Holdings, Inc. (NASDAQ: HTZ) ("Hertz" or the "Company"), a leading global rental car company, today announced that its wholly-owned indirect subsidiary, The Hertz Corporation ("Hertz Corp."), received the requisite consents in its previously announced solicitation of consents ("Consents") to amend (the "Proposed Amendments") certain provisions of the indentures governing its existing 12.625% First Lien Senior Secured Notes due 2029 (the "Initial First Lien Notes") and its 8.000% Exchangeable Senior Second-Lien PIK Notes due 2029 (the "Exchangeable Notes" and, together with the Initial First Lien Notes, the "Existing Notes").

ESTERO, Fla. , Dec. 5, 2024 /PRNewswire/ -- Hertz Global Holdings, Inc. (NASDAQ: HTZ) ("Hertz" or the "Company"), a leading global rental car company, today announced that its wholly-owned indirect subsidiary, The Hertz Corporation ("Hertz Corp."), will solicit consents ("Consents") from the holders of its existing 12.625% First Lien Senior Secured Notes due 2029 (the "Initial First Lien Notes") and the holders of its 8.000% Exchangeable Senior Second-Lien PIK Notes due 2029 (the "Exchangeable Notes" and, together with the Initial First Lien Notes, the "Existing Notes") as of the record date of December 4, 2024 (the "Record Date") to amend (the "Proposed Amendments") certain provisions of the indentures governing the Existing Notes.

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Kidpik Corp. ("KIDPIK" or the "Company"), an online clothing subscription-based e-commerce company, today reported its financial results for the third quarter 2024 ended September 28, 2024. Third Quarter 2024 Highlights: Revenue, net: was $1.0 million, a year-over-year decrease of 69.2%.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Kidpik (Nasdaq: PIK) for possible breaches of fiduciary duty and other violations of law in its transaction with Nina Footwear. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Kidpik will acquire Nina Footwear through a reverse subsidiary merger. Nina Footwear stockholders will be is.

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kidpik Corp. (NASDAQ: PIK ), relating to its proposed merger with Nina Footwear Corp. Under the terms of the agreement, Nina Footwear stockholders will be issued shares of common stock of Kidpik and upon closing, Nina Footwear's stockholders will own 80% of Kidpik's outstanding common stock.

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kidpik Corp. (NASDAQ: PIK), relating to its proposed merger with Nina Footwear Corp. Under the terms of the agreement, shareholders of Kaival Brands will receive 1 share of Pubco for each share of Kaival Brands common stock they own, and are anticipated to own approximately 10.30% of Pubco.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application and granted Priority Review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growt.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic.

NEW YORK--(BUSINESS WIRE)--Kidpik Corp. (“KIDPIK” or the “Company”), an online clothing subscription-based e-commerce company, today reported its financial results for the first quarter 2024 ended March 30, 2024. First Quarter 2024 Highlights: Revenue, net: was $2.2 million, a year over year decrease of 44.4%. Gross margin: was 69.9%, compared to 59.8% in the first quarter of 2023. Shipped items: were 195,000 items, compared to 340,000 shipped items in the first quarter of 2023. Average shipmen.